Cara Therapeutics, Inc. (CARA)
NASDAQ: CARA · Real-Time Price · USD
0.292
-0.005 (-1.75%)
Nov 4, 2024, 4:00 PM EST - Market closed

Cara Therapeutics Revenue

Cara Therapeutics had revenue of $991.00K in the quarter ending June 30, 2024, a decrease of -85.71%. This brings the company's revenue in the last twelve months to $11.00M, down -59.53% year-over-year. In the year 2023, Cara Therapeutics had annual revenue of $20.97M, down -49.92%.

Revenue (ttm)
$11.00M
Revenue Growth
-59.53%
P/S Ratio
1.45
Revenue / Employee
$199,927
Employees
55
Market Cap
16.00M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202320.97M-20.90M-49.92%
Dec 31, 202241.87M18.84M81.81%
Dec 31, 202123.03M-112.05M-82.95%
Dec 31, 2020135.08M115.20M579.28%
Dec 31, 201919.89M6.42M47.64%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Trinity Biotech 58.65M
Cumberland Pharmaceuticals 37.79M
HCW Biologics 3.92M
Lyra Therapeutics 1.82M
Talphera 398.00K
GeoVax Labs 300.68K
AIM ImmunoTech 201.00K
Kazia Therapeutics 382.00
Revenue Rankings